Clinical trials: Aromatase Inhibitors
Breast Cancer
The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Proteins
Single phlebotomy study involving women receiving tamoxifen or aromatase inhibitor therapy.
- Trial name
- NCT01341171
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Vermont
Breast Cancer
Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer
Phase II trial to explore the efficacy of vorinostat and tamoxifen combined.
- Trial name
- NCT00365599
- Testing
- suberoylanilide hydroxamic acid (SAHA, Vorinostat), tamoxifen citrate (Tamoxifen)
- Where
- 8 sites in United States
- Volunteers
- 43 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Neoplasms
Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
The purpose of this study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant in Postmenopausal Women with estrogen receptor positive (ER+), human…
- Trial name
- NCT02374099
- Testing
- CC-486, Fulvestrant
- Where
- 35 sites in United States, Belgium and 4 more
- Volunteers
- 97 people
- Sponsor
- Celgene
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss
This phase II trial tests how well a probiotic, WBF-038, works in preventing bone loss in patients with early-stage hormone receptor-positive breast cancer who are starting treatment with aromatase inhibitors.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT07044310
- Testing
- Biospecimen Collection, Bone Mineral Density Test, Questionnaire Administration
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Mayo Clinic
Metastatic Breast Cancer, ER Positive Breast Cancer
To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
This is a multi-center biomarkers study aiming to prospectively collect biological samples from patients with ER+ and HER2-negative metastatic breast cancer, who are candidate to first-line treatment with an aromatase inhibitor…
- Conditions
- Metastatic Breast Cancer, ER Positive Breast Cancer, HER2-negative Breast Cancer
- Trial name
- TIRESIAS (NCT04660435)
- Testing
- Thymidine kinase activity
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Fondazione Sandro Pitigliani
Metastatic Breast Cancer
Study of ESR1 Mutations in Metastatic Breast Cancer
The purpose of the study is to determine the frequency ESR1 mutations by Digital PCR in patient with metastatic breast cancer.
- Trial name
- FMER (NCT02473120)
- Testing
- Determination of ESR1 mutations
- Where
- France
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Centre Henri Becquerel
Locally Advanced Breast Cancer, Metastatic Breast Cancer
A Study of the Safety and Effectiveness of Irosustat When Added to an AI in ER+ve Locally Advanced or Metastatic Breast Cancer.
70% of breast cancers that occur in postmenopausal women rely on the hormone oestrogen to grow and are likely to respond to hormone treatment.
- Trial name
- IRIS (NCT01785992)
- Testing
- Irosustat
- Where
- 9 sites in United Kingdom
- Volunteers
- 27 people
- Sponsor
- Imperial College London
Breast Cancer, Arthralgia
Treatment for Joint Pains Due to Aromatase Inhibitor Therapy in Breast Cancer
Aromatase inhibitors are the most effective adjuvant anti-hormonal therapy for estrogen receptor positive (ER+) post-menopausal breast cancer patients, with proven superiority over tamoxifen in terms of disease-free survival…
- Conditions
- Breast Cancer, Arthralgia, Joint Pain
- Trial name
- AIA (NCT01612728)
- Testing
- Women without Arthralgia, Women with Arthralgia
- Sponsor
- Baylor Breast Care Center
Breast Neoplasms, Musculoskeletal Pain
Hypnosis to Reduce Aromatase Inhibitor Pain and Improve Adherence
The purpose of this study is to determine whether hypnosis is efficacious in reducing musculoskeletal pain in breast cancer survivors taking aromatase inhibitors, and by doing so, whether hypnosis can help survivors to be more…
- Trial name
- NCT02657993
- Testing
- Hypnosis, Attention Control
- Where
- United States
- Volunteers
- 191 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Metastatic Breast Cancer
Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors
This is an international (4 countries) randomized phase III study with 2 cohorts, patients will be randomized 1:1 to endocrine therapy (cohort 1: exemestane 25 mg daily, cohort 2: fulvestrant 500mg days 1 and 15 cycle 1 and then…
- Trial name
- PEARL (NCT02028507)
- Testing
- Palbociclib, Capecitabine, Exemestane
- Where
- 37 sites in Austria, Hungary and 2 more
- Volunteers
- 693 people
- Sponsor
- Spanish Breast Cancer Research Group
Breast Cancer
Writing Interventions in Breast Cancer Patients Taking Aromatase Inhibitors
Aromatase inhibitors are a powerful medication for reducing the risk of recurrence and increasing survival in postmenopausal breast cancer patients.
- Trial name
- NCT04651452
- Testing
- Value Affirmation, Reflective Journaling
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Carnegie Mellon University
Breast Cancer
The Effect of Grape Seed Extract on Estrogen Levels of Postmenopausal Women
The role of estrogens in the pathogenesis of breast cancer has been well documented. This has led to the development of "Anti-Estrogens" (selective estrogens receptor modulators and Aromatase Inhibitors), used for treatment and…
- Trial name
- NCT00566553
- Testing
- Grape Seed Extract
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Arthralgia, Breast Cancer
Joint Pain and Medication Adherence in Postmenopausal Women Receiving Aromatase Inhibitors
RATIONALE: Gathering information over time about joint pain and stiffness from postmenopausal women with early-stage breast cancer who are receiving aromatase inhibitors may help doctors plan treatment and help patients live more…
- Trial name
- NCT00954564
- Testing
- aromatase inhibition therapy - OBSERVATIONAL ONLY, medical chart review, questionnaire administration
- Where
- 2 sites in United States
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Breast Cancer
Progressive Relaxation Training in Breast Cancer Patients Receiving Aromatatase Inhibitor Therapy
This study evaluates the effects of progressive relaxation exercises on artralgia, quality of life and anxiety-deppression in breast cancer patients receiving aromatase inhibitor.
- Trial name
- PREBCA (NCT04163692)
- Testing
- Progressive relaxation exercises
- Where
- Turkey (Türkiye)
- Volunteers
- 44 people
- Sponsor
- Hacettepe University
Metformin, Breast Cancer
Implication of Metformin Plus Aromatase Inhibitor in Obese Postmenopausal Breast Cancer Women
Metformin is an anti-diabetic oral hypoglycemic agent that considered the gold standard therapy for the treatment of type 2 diabetes.
- Trial name
- NCT05053841
- Testing
- Metformin
- Volunteers
- 45 people
- Sponsor
- Tanta University
Neoplasms, Breast
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
A study to compare the safety and efficacy of an aromatase inhibitor in combination with lapatinib, trastuzumab or both for the treatment of hormone receptor positive, HER2+ metastatic breast cancer (MBC).
- Trial name
- NCT01160211
- Testing
- Lapatinib, Trastuzumab, Aromatase Inhibitor
- Where
- 110 sites in United States, Argentina and 27 more
- Volunteers
- 369 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes
This is a retrospective, observational study that will document the treatment patterns and clinical outcomes of patients diagnosed with HR+/HER2- A/MBC who received CDK4/6i combination therapy with aromatase inhibitors (AI) as…
- Trial name
- NCT04396626
- Where
- United States
- Volunteers
- 975 people
- Sponsor
- Pfizer
Breast Cancer Female, Locally Advanced Breast Cancer
Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer
The purpose of this study is to test the efficacy, safety and tolerability of a combination of immunotherapy and anticancer drugs presurgery in patients with hormone-receptor positive breast cancer.
- Conditions
- Breast Cancer Female, Locally Advanced Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast
- Trial name
- NCT04088032
- Testing
- Abemaciclib, durvalumab and aromatase inhibitor
- Where
- United States
- Sponsor
- Alison Stopeck
Metastatic Breast Cancer
Overcoming Endocrine Resistance in Metastatic Breast Cancer
Based on these results it can be envisioned that the majority of endocrine-responsive post-menopausal breast cancer patients will be treated with an AI as adjuvant therapy (front-line, switching or extending) and/or as first-line…
- Trial name
- OVER (NCT02394496)
- Testing
- Fulvestrant, Lapatinib, Aromatase Inhibitors
- Where
- 69 sites in Italy
- Volunteers
- 396 people
- Sponsor
- Consorzio Oncotech
Breast Cancer, Xerostomia
Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors
The 3 Specific Aims are (1) To determine the prevalence, incidence and severity of oral conditions in postmenopausal early stage breast cancer survivors within the first 18 months of adjuvant Aromatase Inhibitor(AI) therapy, (2)…
- Trial name
- NCT01272570
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- University of Michigan